{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:34:14Z","timestamp":1788449654927,"version":"build-2803163510"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2002,5,14]],"date-time":"2002-05-14T00:00:00Z","timestamp":1021334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Neoplastic meningitis (NM), a metastatic complication of both primary central nervous system and systemic cancer, occurs in 1\u20105% of patients with known cancer. Currently available treatment options are limited and provide only modest benefit. The current study was performed to determine the toxicity and response rate of intra\u2010cerebrospinal fluid (CSF) alpha interferon (\u03b1\u2010IFN) in the treatment of patients with NM.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Twenty two patients (median age, 56 years) with clinical and cytologically documented NM received intra\u2010CSF \u03b1\u2010IFN. Tumor histologies included: lung (five patients); brain (five patients); non\u2010Hodgkin lymphoma (three patients); breast (three patients); melanoma (two patients); chronic myelogenous leukemia (two patients); colon (one patient); and prostate (one patient). Concurrent involved\u2010field radiotherapy (12 out of 22 patients) or systemic chemotherapy (11 out of 22) was administered based on clinical indications. \u2010\u03b1\u2010IFN was administered at a fixed dose (1 \u00d7 10<jats:sup>6<\/jats:sup> IU every other day given three times per week for four weeks by induction). Patients were evaluated by CSF cytology and neurologic examination at the conclusion of induction therapy. Responding patients continued to receive \u03b1\u2010IFN with monthly evaluations.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Ten out of 22 patients (45%) treated with \u03b1\u2010IFN had a cytologic response and either stable or improved neurologic status at the conclusion of induction. Duration of response ranged from 8 to 40 weeks (median, 16 weeks). Toxicity was manifested as transient chemical arachnoiditis (16 out of 22 patients; 60% of all treatment cycles) and chronic fatigue (20 out of 22 patients). No treatment\u2010related hospitalizations or deaths were seen.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>\u03b1\u2010IFN has modest activity against NM. However, it is associated with considerable toxicity at the dose and schedule used in the current study and, as a result, may prove difficult to administer. Cancer 2002;94:2675\u201380. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10547<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10547","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T19:28:18Z","timestamp":1030303698000},"page":"2675-2680","source":"Crossref","is-referenced-by-count":81,"title":["A Phase II trial of intra\u2010cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis"],"prefix":"10.1002","volume":"94","author":[{"given":"Marc C.","family":"Chamberlain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,5,14]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1996.00550070064013"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1994.00540170033013"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(18)30252-4"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.561"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.1987.5.10.1655","article-title":"A prospective randomized trial of single\u2010agent versus combination chemotherapy in meningeal carcinomatosis","volume":"5","author":"Hitchens R","year":"1987","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3110"},{"key":"e_1_2_5_8_2","first-page":"3394","article-title":"A randomized trial comparing intrathecal sustained\u2010release ara\u2010C (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"11","author":"Glantz M","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.1993.11.10.1978","article-title":"Involved field radiotherapy and intra\u2010ommaya methotrexate\/ara\u2010C in patients with AIDS\u2010related lymphomatous meningitis","volume":"11","author":"Chamberlain M","year":"1993","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00254052"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197610)38:4<1471::AID-CNCR2820380404>3.0.CO;2-0"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197507242930402"},{"key":"e_1_2_5_13_2","first-page":"6101","article-title":"Pharmacokinetics of intra\u2010ventricular and intravenous N, N', N\u201c\u2010triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans","volume":"46","author":"Strong J","year":"1986","journal-title":"Cancer Res"},{"key":"e_1_2_5_14_2","first-page":"179","article-title":"Intrathecal interferon alpha 2b in meningeal carcinomatosis","volume":"12","author":"Hankenson R","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_5_15_2","first-page":"138","article-title":"Phase I study of intraventricularly administered human interferon in patients with leptomeningeal tumor","volume":"14","author":"Jaeckle K","year":"1983","journal-title":"Ann Neurol"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910701)68:1<88::AID-CNCR2820680118>3.0.CO;2-5"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.11.1765"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90404-1"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02228887"},{"key":"e_1_2_5_21_2","first-page":"2017","article-title":"High\u2010dose methotrexate: a critical reappraisal","volume":"5","author":"Ackland S","year":"1987","journal-title":"J Oncol"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.9.546"},{"key":"e_1_2_5_23_2","first-page":"39","article-title":"Mood and cognitive side effects of interferon\u2010alpha therapy","volume":"25","author":"Valentine AD","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357909509024923"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103293441303"},{"key":"e_1_2_5_26_2","first-page":"23","article-title":"The effects of interferon\u2010alpha on the production and action of other cytokines","volume":"25","author":"Taylor JL","year":"1998","journal-title":"Semin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10547","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:16:28Z","timestamp":1760289388000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,14]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,5,15]]}},"alternative-id":["10.1002\/cncr.10547"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10547","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,14]]}}}